Testing growth hormone deficiency in adults

Enrico Gabellieri, Luca Chiovato, Mary Lage, Ana I. Castro, Felipe F. Casanueva

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Growth hormone deficiency (GHD) in adults is a recognized syndrome which is defined biochemically within an appropriate clinical context. Clinically, patients investigated for GHD should include those with signs and symptoms of hypothalamic-pituitary disease, those who have received cranial irradiation or tumor treatment and those with traumatic brain injury or subarachnoid hemorrhage. Patients with three or more pituitary hormone deficiencies and an IGF-I below the reference range do not require provocative testing. The other patients need a provocative test of GH secretory reserve for the diagnosis of GHD. Insulin tolerance test is considered the diagnostic test of choice, however, the GH-releasing hormone (GHRH) + arginine, the GHRH + growth hormonereleasing peptide and the glucagon stimulation tests are well validated alternative tests in adults. Cutoffs differ across tests and results may be influenced by gender, age, body mass index, and the assay reference preparation.

Original languageEnglish
Title of host publicationPituitary Today II: New Molecular, Physiological and Clinical Aspects
PublisherS. Karger AG
Pages139-144
Number of pages6
Volume38
ISBN (Print)9783805594455, 9783805594448
DOIs
Publication statusPublished - Jul 7 2010

Fingerprint

Growth Hormone
Traumatic Brain Hemorrhage
Hypothalamic Diseases
Testing
Traumatic Subarachnoid Hemorrhage
Pituitary Diseases
Cranial Irradiation
Pituitary Hormones
Glucagon
Insulin-Like Growth Factor I
Routine Diagnostic Tests
Signs and Symptoms
Arginine
Tumors
Assays
Brain
Reference Values
Body Mass Index
Irradiation
Hormones

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Gabellieri, E., Chiovato, L., Lage, M., Castro, A. I., & Casanueva, F. F. (2010). Testing growth hormone deficiency in adults. In Pituitary Today II: New Molecular, Physiological and Clinical Aspects (Vol. 38, pp. 139-144). S. Karger AG. https://doi.org/10.1159/000318503

Testing growth hormone deficiency in adults. / Gabellieri, Enrico; Chiovato, Luca; Lage, Mary; Castro, Ana I.; Casanueva, Felipe F.

Pituitary Today II: New Molecular, Physiological and Clinical Aspects. Vol. 38 S. Karger AG, 2010. p. 139-144.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gabellieri, E, Chiovato, L, Lage, M, Castro, AI & Casanueva, FF 2010, Testing growth hormone deficiency in adults. in Pituitary Today II: New Molecular, Physiological and Clinical Aspects. vol. 38, S. Karger AG, pp. 139-144. https://doi.org/10.1159/000318503
Gabellieri E, Chiovato L, Lage M, Castro AI, Casanueva FF. Testing growth hormone deficiency in adults. In Pituitary Today II: New Molecular, Physiological and Clinical Aspects. Vol. 38. S. Karger AG. 2010. p. 139-144 https://doi.org/10.1159/000318503
Gabellieri, Enrico ; Chiovato, Luca ; Lage, Mary ; Castro, Ana I. ; Casanueva, Felipe F. / Testing growth hormone deficiency in adults. Pituitary Today II: New Molecular, Physiological and Clinical Aspects. Vol. 38 S. Karger AG, 2010. pp. 139-144
@inbook{0894dffb2b0c418db36c95de2248488f,
title = "Testing growth hormone deficiency in adults",
abstract = "Growth hormone deficiency (GHD) in adults is a recognized syndrome which is defined biochemically within an appropriate clinical context. Clinically, patients investigated for GHD should include those with signs and symptoms of hypothalamic-pituitary disease, those who have received cranial irradiation or tumor treatment and those with traumatic brain injury or subarachnoid hemorrhage. Patients with three or more pituitary hormone deficiencies and an IGF-I below the reference range do not require provocative testing. The other patients need a provocative test of GH secretory reserve for the diagnosis of GHD. Insulin tolerance test is considered the diagnostic test of choice, however, the GH-releasing hormone (GHRH) + arginine, the GHRH + growth hormonereleasing peptide and the glucagon stimulation tests are well validated alternative tests in adults. Cutoffs differ across tests and results may be influenced by gender, age, body mass index, and the assay reference preparation.",
author = "Enrico Gabellieri and Luca Chiovato and Mary Lage and Castro, {Ana I.} and Casanueva, {Felipe F.}",
year = "2010",
month = "7",
day = "7",
doi = "10.1159/000318503",
language = "English",
isbn = "9783805594455",
volume = "38",
pages = "139--144",
booktitle = "Pituitary Today II: New Molecular, Physiological and Clinical Aspects",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Testing growth hormone deficiency in adults

AU - Gabellieri, Enrico

AU - Chiovato, Luca

AU - Lage, Mary

AU - Castro, Ana I.

AU - Casanueva, Felipe F.

PY - 2010/7/7

Y1 - 2010/7/7

N2 - Growth hormone deficiency (GHD) in adults is a recognized syndrome which is defined biochemically within an appropriate clinical context. Clinically, patients investigated for GHD should include those with signs and symptoms of hypothalamic-pituitary disease, those who have received cranial irradiation or tumor treatment and those with traumatic brain injury or subarachnoid hemorrhage. Patients with three or more pituitary hormone deficiencies and an IGF-I below the reference range do not require provocative testing. The other patients need a provocative test of GH secretory reserve for the diagnosis of GHD. Insulin tolerance test is considered the diagnostic test of choice, however, the GH-releasing hormone (GHRH) + arginine, the GHRH + growth hormonereleasing peptide and the glucagon stimulation tests are well validated alternative tests in adults. Cutoffs differ across tests and results may be influenced by gender, age, body mass index, and the assay reference preparation.

AB - Growth hormone deficiency (GHD) in adults is a recognized syndrome which is defined biochemically within an appropriate clinical context. Clinically, patients investigated for GHD should include those with signs and symptoms of hypothalamic-pituitary disease, those who have received cranial irradiation or tumor treatment and those with traumatic brain injury or subarachnoid hemorrhage. Patients with three or more pituitary hormone deficiencies and an IGF-I below the reference range do not require provocative testing. The other patients need a provocative test of GH secretory reserve for the diagnosis of GHD. Insulin tolerance test is considered the diagnostic test of choice, however, the GH-releasing hormone (GHRH) + arginine, the GHRH + growth hormonereleasing peptide and the glucagon stimulation tests are well validated alternative tests in adults. Cutoffs differ across tests and results may be influenced by gender, age, body mass index, and the assay reference preparation.

UR - http://www.scopus.com/inward/record.url?scp=84926103659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926103659&partnerID=8YFLogxK

U2 - 10.1159/000318503

DO - 10.1159/000318503

M3 - Chapter

SN - 9783805594455

SN - 9783805594448

VL - 38

SP - 139

EP - 144

BT - Pituitary Today II: New Molecular, Physiological and Clinical Aspects

PB - S. Karger AG

ER -